Middle East respiratory syndrome coronavirus: five years later.
Identifieur interne : 000C82 ( Main/Exploration ); précédent : 000C81; suivant : 000C83Middle East respiratory syndrome coronavirus: five years later.
Auteurs : Ali A. Rabaan [Arabie saoudite]Source :
- Expert review of respiratory medicine [ 1747-6356 ] ; 2017.
Descripteurs français
- KwdFr :
- MESH :
- pathogénicité : Coronavirus du syndrome respiratoire du Moyen-Orient.
- épidémiologie : Infections à coronavirus, Moyen Orient.
- Flambées de maladies, Humains, Infections à coronavirus, Lutte contre l'infection.
English descriptors
- KwdEn :
- MESH :
- epidemiology : Coronavirus Infections, Middle East.
- pathogenicity : Middle East Respiratory Syndrome Coronavirus.
- prevention & control : Coronavirus Infections.
- transmission : Coronavirus Infections.
- Disease Outbreaks, Humans, Infection Control.
Abstract
In the past five years, there have been 1,936 laboratory-confirmed cases of Middle East Respiratory Syndrome coronavirus (MERS-CoV) in 27 countries, with a mortality rate of 35.6%. Most cases have arisen in the Middle East, particularly the Kingdom of Saudi Arabia, however there was a large hospital-associated outbreak in the Republic of Korea in 2015. Exposure to dromedary camels has been recognized by the World Health Organization (WHO) as a risk factor in primary cases, but the exact mechanisms of transmission are not clear. Rigorous application of nationally defined infection prevention and control measures has reduced the levels of healthcare facility-associated outbreaks. There is currently no approved specific therapy or vaccine available. Areas covered: This review presents an overview of MERS-CoV within the last five years, with a particular emphasis on the key areas of transmission, infection control and prevention, and therapies and vaccines. Expert commentary: MERS-CoV remains a significant threat to public health as transmission mechanisms are still not completely understood. There is the potential for mutations that could increase viral transmission and/or virulence, and zoonotic host range. The high mortality rate highlights the need to expedite well-designed randomized clinical trials for direct, effective therapies and vaccines.
DOI: 10.1080/17476348.2017.1367288
PubMed: 28826284
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000B91
- to stream PubMed, to step Curation: 000B91
- to stream PubMed, to step Checkpoint: 000C12
- to stream Ncbi, to step Merge: 001B44
- to stream Ncbi, to step Curation: 001B44
- to stream Ncbi, to step Checkpoint: 001B44
- to stream Main, to step Merge: 000C85
- to stream Main, to step Curation: 000C82
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Middle East respiratory syndrome coronavirus: five years later.</title><author><name sortKey="Rabaan, Ali A" sort="Rabaan, Ali A" uniqKey="Rabaan A" first="Ali A" last="Rabaan">Ali A. Rabaan</name><affiliation wicri:level="1"><nlm:affiliation>a Molecular Diagnostic Laboratory , Johns Hopkins Aramco Healthcare , Dhahran , Saudi Arabia.</nlm:affiliation><country xml:lang="fr">Arabie saoudite</country><wicri:regionArea>a Molecular Diagnostic Laboratory , Johns Hopkins Aramco Healthcare , Dhahran </wicri:regionArea><wicri:noRegion>Dhahran </wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:28826284</idno><idno type="pmid">28826284</idno><idno type="doi">10.1080/17476348.2017.1367288</idno><idno type="wicri:Area/PubMed/Corpus">000B91</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000B91</idno><idno type="wicri:Area/PubMed/Curation">000B91</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000B91</idno><idno type="wicri:Area/PubMed/Checkpoint">000C12</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000C12</idno><idno type="wicri:Area/Ncbi/Merge">001B44</idno><idno type="wicri:Area/Ncbi/Curation">001B44</idno><idno type="wicri:Area/Ncbi/Checkpoint">001B44</idno><idno type="wicri:Area/Main/Merge">000C85</idno><idno type="wicri:Area/Main/Curation">000C82</idno><idno type="wicri:Area/Main/Exploration">000C82</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Middle East respiratory syndrome coronavirus: five years later.</title><author><name sortKey="Rabaan, Ali A" sort="Rabaan, Ali A" uniqKey="Rabaan A" first="Ali A" last="Rabaan">Ali A. Rabaan</name><affiliation wicri:level="1"><nlm:affiliation>a Molecular Diagnostic Laboratory , Johns Hopkins Aramco Healthcare , Dhahran , Saudi Arabia.</nlm:affiliation><country xml:lang="fr">Arabie saoudite</country><wicri:regionArea>a Molecular Diagnostic Laboratory , Johns Hopkins Aramco Healthcare , Dhahran </wicri:regionArea><wicri:noRegion>Dhahran </wicri:noRegion></affiliation></author></analytic><series><title level="j">Expert review of respiratory medicine</title><idno type="eISSN">1747-6356</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Coronavirus Infections (epidemiology)</term><term>Coronavirus Infections (prevention & control)</term><term>Coronavirus Infections (transmission)</term><term>Disease Outbreaks</term><term>Humans</term><term>Infection Control</term><term>Middle East (epidemiology)</term><term>Middle East Respiratory Syndrome Coronavirus (pathogenicity)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Coronavirus du syndrome respiratoire du Moyen-Orient (pathogénicité)</term><term>Flambées de maladies</term><term>Humains</term><term>Infections à coronavirus ()</term><term>Infections à coronavirus (transmission)</term><term>Infections à coronavirus (épidémiologie)</term><term>Lutte contre l'infection</term><term>Moyen Orient (épidémiologie)</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Coronavirus Infections</term><term>Middle East</term></keywords><keywords scheme="MESH" qualifier="pathogenicity" xml:lang="en"><term>Middle East Respiratory Syndrome Coronavirus</term></keywords><keywords scheme="MESH" qualifier="pathogénicité" xml:lang="fr"><term>Coronavirus du syndrome respiratoire du Moyen-Orient</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Coronavirus Infections</term></keywords><keywords scheme="MESH" qualifier="transmission" xml:lang="en"><term>Coronavirus Infections</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Infections à coronavirus</term><term>Moyen Orient</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Disease Outbreaks</term><term>Humans</term><term>Infection Control</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Flambées de maladies</term><term>Humains</term><term>Infections à coronavirus</term><term>Lutte contre l'infection</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">In the past five years, there have been 1,936 laboratory-confirmed cases of Middle East Respiratory Syndrome coronavirus (MERS-CoV) in 27 countries, with a mortality rate of 35.6%. Most cases have arisen in the Middle East, particularly the Kingdom of Saudi Arabia, however there was a large hospital-associated outbreak in the Republic of Korea in 2015. Exposure to dromedary camels has been recognized by the World Health Organization (WHO) as a risk factor in primary cases, but the exact mechanisms of transmission are not clear. Rigorous application of nationally defined infection prevention and control measures has reduced the levels of healthcare facility-associated outbreaks. There is currently no approved specific therapy or vaccine available. Areas covered: This review presents an overview of MERS-CoV within the last five years, with a particular emphasis on the key areas of transmission, infection control and prevention, and therapies and vaccines. Expert commentary: MERS-CoV remains a significant threat to public health as transmission mechanisms are still not completely understood. There is the potential for mutations that could increase viral transmission and/or virulence, and zoonotic host range. The high mortality rate highlights the need to expedite well-designed randomized clinical trials for direct, effective therapies and vaccines.</div></front></TEI><affiliations><list><country><li>Arabie saoudite</li></country></list><tree><country name="Arabie saoudite"><noRegion><name sortKey="Rabaan, Ali A" sort="Rabaan, Ali A" uniqKey="Rabaan A" first="Ali A" last="Rabaan">Ali A. Rabaan</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000C82 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000C82 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= MersV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:28826284
|texte= Middle East respiratory syndrome coronavirus: five years later.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:28826284" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a MersV1
| This area was generated with Dilib version V0.6.33. |  |